IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial February 23, 2026 Read More »
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis June 11, 2026 Read More »
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts June 9, 2026 Read More »
